Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168791 · ClinicalTrials.gov registry record · Phase 3
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
A Phase 3 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT01168791: Completed Phase 3 study, sponsored by Alaunos Therapeutics.
NCT01168791 is a Phase 3 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 447 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01168791, a Phase 3 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).
Interventions
- DRUG doxorubicin in combination with palifosfamide-tris
- DRUG doxorubicin in combination with placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
What the finished NCT01168791 record still lists
NCT01168791 is an interventional study that assigns participants to a tested intervention. The registered 447 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which doxorubicin in combination with palifosfamide-tris is the first listed.
NCT01168791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01168791 about?
NCT01168791 is a clinical study titled "Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma". This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma ...
What is the current status of trial NCT01168791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2010-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01168791?
The interventions under investigation include: doxorubicin in combination with palifosfamide-tris (DRUG), doxorubicin in combination with placebo (DRUG).
Who is sponsoring clinical trial NCT01168791?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01168791's enrollment target sits among peer trials
447 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia